NAD+ Precursors vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: NMN, NR
While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Key Comparison Insights
- SS-31 is FDA approved, while NAD+ Precursors remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to NAD+ Precursors (Human Trials).
Detailed Comparison
| Attribute | NAD+ Precursors | SS-31 |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NMN and NR are converted to NAD+ in cells. NAD+ is essential for mitochondrial function, DNA repair, and sirtuin enzyme activity. Sirtuins regulate metabolism, stress response, and longevity pathways. NAD+ levels decline with age. | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. |
| Common Dosing | Limited community data available See research protocols | 40 mg subcutaneous daily Once daily |
| Administration | Oral (capsules, sublingual) | Subcutaneous injection or IV infusion |
| Typical Duration | Ongoing supplementation | Variable by condition |
| Best Time to Take | Morning or before bed | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Animal studies show improved metabolic function, enhanced exercise capacity, and extended healthspan. Human trials demonstrate safety and NAD+ elevation. Long-term benefits in humans still being established. David Sinclair's research popularized the field. | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. |
Frequently Asked Questions: NAD+ Precursors vs SS-31
What is the difference between NAD+ Precursors and SS-31?
NAD+ Precursors is a anti-aging peptide that while not peptides, nad+ precursors are frequently discussed alongside peptides in longevity circles. they boost cellular nad+ levels, supporting energy metabolism and sirtuin activity. SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. The main differences lie in their mechanisms of action and clinical applications.
Which is better, NAD+ Precursors or SS-31?
Neither is universally "better" - the choice depends on your specific goals. NAD+ Precursors is typically used for anti-aging purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can NAD+ Precursors and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using NAD+ Precursors and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of NAD+ Precursors and SS-31 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.